The idea of allogeneic (off-of-shelf) immune cells facilitates pharmaceutics for cancer treatment but it needs to overcome transplanted cell rejection. Recently autologous immune cell therapies such as FDA approved CAR-T (chimeric antigen receptor T cells), Kymriah and Yescarta, have displayed promising efficacy to cure blood cancer, but their safety and cost issues indeed influence use of CAR-T. Notably, there are tremendous efforts to generate allogeneic CAR-T to avoid the rejection, which indicates it impedes CAR-T to work out in pharmaceutical industry. 

Dendritic cell (DC)-based cancer therapy aims to target heterogenous tumor cells and activate immune systems, in order to effectively eliminate solid cancer progression. Moreover, unlike CAR-T, DC is genetic engineering independent, as well as displays more allogeneic immune tolerance, which increases possibility to industrialize allogeneic DC for anti-cancer drugs. Nevertheless, the abovementioned idea still requires some innovations to produce the safe DC for clinical use. Unfortunately, almost all DC therapies are autologous, and current clinical allogeneic DC studies could not guarantee their safety and industrialization. Here we provide a breakthrough to manufacture large-scale of safe allogeneic DCs for cancer treatment. The outcome of the innovative manufacturing process will produce affordable anti-tumor drugs to benefit global patients suffering from refractory solid tumors.

I am CEO and Founder of Celtec Inc. which is a pre-clinical stage company and focus cutting-edge dendritic cell (DC)-based immunotherapy with personal tumor antigens. The company was funded with the mission to significantly improve life and its quality in advanced cancer patients, because they are almost hopeless to be cured. Our innovative immunotherapy will precisely hit cancer cells carrying multiple disease factors to display comfortable efficacy. 

Before I funded Celtec, I was work with late Dr. Judah Folkman at Harvard Medical School. Judah Folkman, M.D. (1933-2008), known as the father of angiogenesis research. Three angiogenesis inhibitors, bevacizumab (Avastin), ranibizumab (Lucentis) and ranibizumab (Eylea) were the first to be approved by the U.S. Food and Drug Administration and are now playing a major role in treatment. 

After that, I serviced as Vice President at both Synovel Biosciences Inc. and Fountain Biopharma Inc. Synovel was using ImmuEdit Aptamer TM to target several highly potential immune checkpoint drug targets for cancer treatment. Fountain Biopharma Inc. was an antibody-based drug discovery biotech company. My team generated a largest fully-human antibody library and developed a first anti-IL6 monoclonal antibody in Asia Pacific area based on this technology platform, and this project is in clinical stage at the US. Those two companies were merged by Oneness Biotech Co. Ltd. this year.